Clinical experiment designed to assess clinical efficacy targeting N/A in pregnant and postpartum women. Primary outcome: maternal antidepressant efficacy and maternal-fetal safety
Clinical evaluation of ketamine and esketamine use in pregnant and postpartum women with treatment-resistant depression. This critical population study examined the safety and efficacy of NMDA receptor antagonists during pregnancy and the postpartum period, addressing the unique challenges of treating depression in women during reproductive years. The research considered maternal and fetal safety profiles, potential teratogenic effects, impacts on pregnancy outcomes, and the critical need for effective depression treatment during this vulnerable period when conventional treatments may be contraindicated or ineffective.
Careful administration of ketamine/esketamine with intensive maternal and fetal monitoring
Effective depression treatment with acceptable maternal-fetal safety profile
Antidepressant efficacy without significant maternal or fetal adverse outcomes
No related hypotheses
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.